查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2031 年亞太地區藥物動力學服務市場預測 - 區域分析 - 按藥物類型、服務類型、治療應用和最終用戶
市場調查報告書
商品編碼
1597064

2031 年亞太地區藥物動力學服務市場預測 - 區域分析 - 按藥物類型、服務類型、治療應用和最終用戶

Asia Pacific Pharmacokinetics Services Market Forecast to 2031 - Regional Analysis - by Drug Type, Service Type, Therapeutic Application, and End User
出版日期: | 出版商: The Insight Partners | 英文 95 Pages | 訂單完成後即時交付

價格

2023年亞太藥物動力學服務市場價值1.9144億美元，預計2031年將達到3.5658億美元；預計2023年至2031年複合年成長率為8.1%。

擴大採用體內和體外模型來了解藥物動力學的變異性，推動亞太藥物動力學服務市場的發展

收集和處理藥物製造過程中產生的大量藥物動力學資料是一項昂貴、繁瑣且耗時的任務。這些任務的勞動力和成本密集性質凸顯了對用於預測藥物動力學參數的藥物動力學模擬模型和體外-體內藥物動力學相關模型（IVIVC）等模型的需求。藥物動力學模擬模型是利用計算和數學模型解釋特定條件下生活環境中藥物動力學的工具。此外，IVIVC 模型是藥物發現過程的基本組成部分。在藥物開發的早期階段分析 PK/PD 預測對於先導最佳化策略和進一步降低損耗率是必要的。在開發新的體外和體內策略以改善和表徵藥物動力學特性方面取得了重大進展。 IVIVC 模型被提議作為一種經濟高效的替代方案，用於評估生物製藥特性，分析藥物的生物利用度及其應用。因此，此類體內和體外模型預計將在不久的將來為亞太藥物動力學服務市場提供利潤豐厚的機會。

亞太地區藥物動力學服務市場概況

中國亞太藥代動力學服務市場的成長主要歸因於成熟的醫藥市場、製藥和生物製藥公司研發支出的增加、營運成本降低導致的臨床試驗數量增加以及有利的監管政策。根據EFPIA 2023年發布的報告，中國製藥公司的研發支出從2020年的108.1423億美元成長到2021年的129.8923億美元。中國人口過多，加上各種非傳染性疾病和傳染病病例的增加，刺激了對新藥物分子的需求，這使中國成為亞太地區的主要市場。

亞太地區藥物動力學服務市場收入及 2031 年預測（百萬美元）

亞太地區藥物動力學服務市場細分

亞太地區藥物動力學服務市場分為藥物類型、服務類型、治療應用、最終用戶和國家。

根據藥物類型，亞太地區藥物動力學服務市場可分為小分子、大分子和疫苗。 2023 年，小分子細分市場佔據最大的市場佔有率。

從服務類型來看，亞太地區藥物動力學服務市場分為臨床前ADME與人體研究、PK/PD分析與報告、給藥模擬、風險分析等。 2023 年，臨床前 ADME 和人體研究領域佔據最大的市場佔有率。

依治療應用，亞太藥物動力學服務市場分為腫瘤學、傳染病、神經系統疾病、自體免疫疾病、婦科疾病、心血管疾病、呼吸系統疾病等。 2023 年，腫瘤學領域佔據最大的市場佔有率。

依最終用戶分類，亞太地區藥物動力學服務市場分為製藥和生技公司、合約研究組織等。 2023 年，合約研究組織細分市場佔據最大的市場佔有率。

依國家/地區分類，亞太地區藥物動力學服務市場分為中國、日本、印度、澳洲、韓國和亞太其他地區。 2023 年，日本在亞太藥物動力學服務市場佔有率中佔據主導地位。

艾倫特；塞塔拉公司；查爾斯河實驗室國際公司； Eurofins Scientific SE；太平洋生物實驗室； Parexel國際公司； SGS SA；上海美迪西生物科技有限公司；和 Thermo Fisher Scientific Inc. 是亞太地區藥物動力學服務市場上的一些領先公司。

目錄

第 1 章：簡介

第 2 章：執行摘要

  • 主要見解

第 3 章：研究方法

  • 覆蓋範圍
  • 二次研究
  • 初步研究

第 4 章：亞太地區藥物動力學服務市場 - 主要市場動態

  • 市場促進因素
    • 慢性病和傳染病的盛行率上升
    • 擴大藥物動力學研究的應用範圍
    • 將藥物動力學服務外包給 CRO
  • 市場限制
    • 新興國家藥物動力學服務提供者的覆蓋範圍有限
  • 市場機會
    • 擴大採用體內和體外模型來了解藥物動力學的變異性
  • 未來趨勢
    • 藥物動力學服務中越來越多採用巨量資料分析
  • 促進因素和限制的影響：

第 5 章：藥物動力學服務市場 - 亞太地區分析

  • 亞太地區藥物動力學服務市場概況
  • 2021-2031 年亞太地區藥物動力學服務市場收入

第 6 章：亞太地區藥物動力學服務市場分析 - 按藥物類型

  • 概述
  • 小分子
  • 大分子
  • 疫苗

第 7 章：亞太地區藥物動力學服務市場分析 - 按服務類型

  • 概述
  • 臨床前 ADME 和人體研究
  • PK/PD 分析和報告
  • 劑量模擬
  • 風險分析
  • 其他

第 8 章：亞太地區藥物動力學服務市場分析 - 按治療應用

  • 腫瘤學
  • 傳染病
  • 神經系統疾病
  • 自體免疫疾病
  • 婦科疾病
  • 心血管疾病
  • 呼吸系統疾病
  • 其他

第 9 章：亞太地區藥物動力學服務市場分析 - 按最終用戶

  • 製藥和生物技術公司
  • 合約研究組織
  • 其他

第 10 章：亞太地區藥物動力學服務市場 - 國家分析

  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 亞太地區其他地區

第 11 章：公司簡介

  • Charles River Laboratories International Inc
  • Eurofins Scientific SE
  • Certara Inc.
  • Parexel International Corp
  • Thermo Fisher Scientific Inc.
  • Allucent
  • PACIFIC BIOLABS
  • SGS SA
  • Shanghai Medicilon Inc.

第 12 章：附錄

Product Code: BMIRE00030886

The Asia Pacific pharmacokinetics services market was valued at US$ 191.44 million in 2023 and is expected to reach US$ 356.58 million by 2031; it is estimated to register a CAGR of 8.1% from 2023 to 2031.

Increasing Adoption of In-Vivo and In-Vitro Models for Understanding Variability in Pharmacokinetics Boost Asia Pacific Pharmacokinetics Services Market

The collection and handling of huge pharmacokinetic data generated during drug manufacturing are expensive, tedious, and time-consuming tasks. The labor- and cost-intensive nature of these tasks highlights the need for models such as pharmacokinetic simulation models and in vitro-in vivo pharmacokinetic correlation models (IVIVC) for the prediction of pharmacokinetic parameters. The pharmacokinetic simulation model is a tool that interprets drug kinetics in the living environment under specific conditions using computational and mathematical models. In addition, the IVIVC model are a fundamental part of the drug discovery process. Analyzing PK/PD predictions at the early stages of drug development is necessary for lead optimization strategies and also to further reduce attrition rates. There have been significant advancements in the development of new in-vitro and in-vivo strategies to improve and characterize pharmacokinetic properties. IVIVC models are being proposed as a cost-effective alternative to assess the biopharmaceutical properties that analyze the bioavailability of drugs and their application. Hence, such in-vivo and in-vitro models are anticipated to provide lucrative opportunities for the Asia Pacific pharmacokinetics services market in the near future.

Asia Pacific Pharmacokinetics Services Market Overview

The Asia Pacific pharmacokinetics services market growth in China is primarily attributed to the established pharmaceutical market, increasing R&D expenditures by pharmaceutical and biopharmaceutical companies, rising number of clinical trials due to lower operating costs, and favorable regulatory policies in place. According to the EFPIA report published in 2023, R&D expenditure by pharmaceutical companies in China grew from US$ 10,814.23 million in 2020 to US$ 12,989.23 million in 2021. China has the world's second-largest pharmaceutical market. The excessive population in the country, coupled with a rise in the cases of various noncommunicable and infectious diseases, fuels the need for new drug molecules, which makes China a prime market in Asia Pacific.

Asia Pacific Pharmacokinetics Services Market Revenue and Forecast to 2031 (US$ Million)

Asia Pacific Pharmacokinetics Services Market Segmentation

The Asia Pacific pharmacokinetics services market is categorized into drug type, service type, therapeutic application, end user, and country.

Based on drug type, the Asia Pacific pharmacokinetics services market is segmented small molecule, large molecule, and vaccines. The small molecule segment held the largest market share in 2023.

In terms of service type, the Asia Pacific pharmacokinetics services market is categorized into pre-clinical ADME and human studies, PK/PD analysis and reporting, dosing simulations, risk analysis, and others. The pre-clinical ADME and human studies segment held the largest market share in 2023.

By therapeutic application, the Asia Pacific pharmacokinetics services market is segmented into oncology, infectious diseases, neurological disorders, autoimmune diseases, gynaecological disorders, cardiovascular diseases, respiratory disorders, and others. The oncology segment held the largest market share in 2023.

By end user, the Asia Pacific pharmacokinetics services market is segmented into pharmaceutical and biotechnology companies, contract research organization, and others. The contract research organization segment held the largest market share in 2023.

By country, the Asia Pacific pharmacokinetics services market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. Japan dominated the Asia Pacific pharmacokinetics services market share in 2023.

Allucent; Certara Inc.; Charles River Laboratories International Inc; Eurofins Scientific SE; PACIFIC BIOLABS; Parexel International Corp; SGS SA; Shanghai Medicilon Inc.; and Thermo Fisher Scientific Inc. are some of the leading companies operating in the Asia Pacific pharmacokinetics services market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Asia Pacific Pharmacokinetics Services Market - Key Market Dynamics

  • 4.1 Market Drivers
    • 4.1.1 Rising Prevalence of Chronic and Infectious Diseases
    • 4.1.2 Expanding Range of Application of Pharmacokinetic Studies
    • 4.1.3 Outsourcing of Pharmacokinetics Services to CROs
  • 4.2 Market Restraints
    • 4.2.1 Limited Reach of Pharmacokinetics Service Providers in Emerging Countries
  • 4.3 Market Opportunities
    • 4.3.1 Increasing Adoption of In-Vivo and In-Vitro Models for Understanding Variability in Pharmacokinetics
  • 4.4 Future Trend
    • 4.4.1 Increasing Adoption of Big Data Analytics in Pharmacokinetics Services
  • 4.5 Impact of Drivers and Restraints:

5. Pharmacokinetics Services Market - Asia Pacific Analysis

  • 5.1 Asia Pacific Pharmacokinetics Services Market Overview
  • 5.2 Asia Pacific Pharmacokinetics Services Market Revenue (US$ Million), 2021-2031

6. Asia Pacific Pharmacokinetics Services Market Analysis - by Drug Type

  • 6.1 Overview
  • 6.2 Small Molecule
    • 6.2.1 Overview
    • 6.2.2 Small Molecule: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.3 Large Molecule
    • 6.3.1 Overview
    • 6.3.2 Large Molecule: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.4 Vaccines
    • 6.4.1 Overview
    • 6.4.2 Vaccines: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

7. Asia Pacific Pharmacokinetics Services Market Analysis - by Service Type

  • 7.1 Overview
  • 7.2 Pre-Clinical ADME and Human Studies
    • 7.2.1 Overview
    • 7.2.2 Pre-Clinical ADME and Human Studies: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.3 PK/PD Analysis and Reporting
    • 7.3.1 Overview
    • 7.3.2 PK/PD Analysis and Reporting: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.4 Dosing Simulations
    • 7.4.1 Overview
    • 7.4.2 Dosing Simulations: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.5 Risk Analysis
    • 7.5.1 Overview
    • 7.5.2 Risk Analysis: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.6 Others
    • 7.6.1 Overview
    • 7.6.2 Others: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

8. Asia Pacific Pharmacokinetics Services Market Analysis - by Therapeutic Application

  • 8.1 Oncology
    • 8.1.1 Overview
    • 8.1.2 Oncology: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.2 Infectious Diseases
    • 8.2.1 Overview
    • 8.2.2 Infectious Diseases: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.3 Neurological Disorders
    • 8.3.1 Overview
    • 8.3.2 Neurological Disorders: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.4 Autoimmune Diseases
    • 8.4.1 Overview
    • 8.4.2 Autoimmune Diseases: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.5 Gynecological Disorders
    • 8.5.1 Overview
    • 8.5.2 Gynecological Disorders: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.6 Cardiovascular Diseases
    • 8.6.1 Overview
    • 8.6.2 Cardiovascular Diseases: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.7 Respiratory Disorders
    • 8.7.1 Overview
    • 8.7.2 Respiratory Disorders: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.8 Others
    • 8.8.1 Overview
    • 8.8.2 Others: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

9. Asia Pacific Pharmacokinetics Services Market Analysis - by End User

  • 9.1 Pharmaceutical and Biotechnology Companies
    • 9.1.1 Overview
    • 9.1.2 Pharmaceutical and Biotechnology Companies: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.2 Contract Research Organization
    • 9.2.1 Overview
    • 9.2.2 Contract Research Organization: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.3 Others
    • 9.3.1 Overview
    • 9.3.2 Others: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

10. Asia Pacific Pharmacokinetics Services Market - Country Analysis

  • 10.1 Asia Pacific
    • 10.1.1 Asia Pacific Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
      • 10.1.1.1 China: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.1.1 Overview
        • 10.1.1.1.2 China: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.1.3 China: Asia Pacific Pharmacokinetics Services Market Breakdown, by Drug Type
        • 10.1.1.1.4 China: Asia Pacific Pharmacokinetics Services Market Breakdown, by Service Type
        • 10.1.1.1.5 China: Asia Pacific Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 10.1.1.1.6 China: Asia Pacific Pharmacokinetics Services Market Breakdown, by End User
      • 10.1.1.2 Japan: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.2.1 Overview
        • 10.1.1.2.2 Japan: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.2.3 Japan: Asia Pacific Pharmacokinetics Services Market Breakdown, by Drug Type
        • 10.1.1.2.4 Japan: Asia Pacific Pharmacokinetics Services Market Breakdown, by Service Type
        • 10.1.1.2.5 Japan: Asia Pacific Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 10.1.1.2.6 Japan: Asia Pacific Pharmacokinetics Services Market Breakdown, by End User
      • 10.1.1.3 India: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.3.1 Overview
        • 10.1.1.3.2 India: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.3.3 India: Asia Pacific Pharmacokinetics Services Market Breakdown, by Drug Type
        • 10.1.1.3.4 India: Asia Pacific Pharmacokinetics Services Market Breakdown, by Service Type
        • 10.1.1.3.5 India: Asia Pacific Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 10.1.1.3.6 India: Asia Pacific Pharmacokinetics Services Market Breakdown, by End User
      • 10.1.1.4 Australia: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.4.1 Overview
        • 10.1.1.4.2 Australia: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.4.3 Australia: Asia Pacific Pharmacokinetics Services Market Breakdown, by Drug Type
        • 10.1.1.4.4 Australia: Asia Pacific Pharmacokinetics Services Market Breakdown, by Service Type
        • 10.1.1.4.5 Australia: Asia Pacific Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 10.1.1.4.6 Australia: Asia Pacific Pharmacokinetics Services Market Breakdown, by End User
      • 10.1.1.5 South Korea: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.5.1 Overview
        • 10.1.1.5.2 South Korea: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.5.3 South Korea: Asia Pacific Pharmacokinetics Services Market Breakdown, by Drug Type
        • 10.1.1.5.4 South Korea: Asia Pacific Pharmacokinetics Services Market Breakdown, by Service Type
        • 10.1.1.5.5 South Korea: Asia Pacific Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 10.1.1.5.6 South Korea: Asia Pacific Pharmacokinetics Services Market Breakdown, by End User
      • 10.1.1.6 Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.6.1 Overview
        • 10.1.1.6.2 Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.6.3 Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market Breakdown, by Drug Type
        • 10.1.1.6.4 Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market Breakdown, by Service Type
        • 10.1.1.6.5 Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 10.1.1.6.6 Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market Breakdown, by End User

11. Company Profile

  • 11.1 Charles River Laboratories International Inc
    • 11.1.1 Key Facts
    • 11.1.2 Business Description
    • 11.1.3 Products and Services
    • 11.1.4 Financial Overview
    • 11.1.5 SWOT Analysis
    • 11.1.6 Key Developments
  • 11.2 Eurofins Scientific SE
    • 11.2.1 Key Facts
    • 11.2.2 Business Description
    • 11.2.3 Products and Services
    • 11.2.4 Financial Overview
    • 11.2.5 SWOT Analysis
    • 11.2.6 Key Developments
  • 11.3 Certara Inc.
    • 11.3.1 Key Facts
    • 11.3.2 Business Description
    • 11.3.3 Products and Services
    • 11.3.4 Financial Overview
    • 11.3.5 SWOT Analysis
  • 11.4 Parexel International Corp
    • 11.4.1 Key Facts
    • 11.4.2 Business Description
    • 11.4.3 Products and Services
    • 11.4.4 Financial Overview
    • 11.4.5 SWOT Analysis
    • 11.4.6 Key Developments
  • 11.5 Thermo Fisher Scientific Inc.
    • 11.5.1 Key Facts
    • 11.5.2 Business Description
    • 11.5.3 Products and Services
    • 11.5.4 Financial Overview
    • 11.5.5 SWOT Analysis
    • 11.5.6 Key Developments
  • 11.6 Allucent
    • 11.6.1 Key Facts
    • 11.6.2 Business Description
    • 11.6.3 Products and Services
    • 11.6.4 Financial Overview
    • 11.6.5 SWOT Analysis
    • 11.6.6 Key Developments
  • 11.7 PACIFIC BIOLABS
    • 11.7.1 Key Facts
    • 11.7.2 Business Description
    • 11.7.3 Products and Services
    • 11.7.4 Financial Overview
    • 11.7.5 SWOT Analysis
    • 11.7.6 Key Developments
  • 11.8 SGS SA
    • 11.8.1 Key Facts
    • 11.8.2 Business Description
    • 11.8.3 Products and Services
    • 11.8.4 Financial Overview
    • 11.8.5 SWOT Analysis
    • 11.8.6 Key Developments
  • 11.9 Shanghai Medicilon Inc.
    • 11.9.1 Key Facts
    • 11.9.2 Business Description
    • 11.9.3 Products and Services
    • 11.9.4 Financial Overview
    • 11.9.5 SWOT Analysis
    • 11.9.6 Key Developments

12. Appendix

  • 12.1 About The Insight Partners
  • 12.2 Glossary of Terms for Pharmacokinetic Services Market

List Of Tables

  • Table 1. Asia Pacific Pharmacokinetics Services Market Segmentation
  • Table 2. China: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
  • Table 3. China: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
  • Table 4. China: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
  • Table 5. China: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
  • Table 6. Japan: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
  • Table 7. Japan: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
  • Table 8. Japan: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
  • Table 9. Japan: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
  • Table 10. R&D Expenditure of Indian Companies, 2018-2020 (US$ Million)
  • Table 11. India: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
  • Table 12. India: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
  • Table 13. India: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
  • Table 14. India: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
  • Table 15. Australia: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
  • Table 16. Australia: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
  • Table 17. Australia: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
  • Table 18. Australia: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
  • Table 19. South Korea: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
  • Table 20. South Korea: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
  • Table 21. South Korea: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
  • Table 22. South Korea: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
  • Table 23. Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
  • Table 24. Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
  • Table 25. Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
  • Table 26. Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
  • Table 27. Glossary of Terms

List Of Figures

  • Figure 1. Asia Pacific Pharmacokinetics Services Market Segmentation, by Country
  • Figure 2. Asia Pacific Pharmacokinetics Services Market - Key Market Dynamics
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Asia Pacific Pharmacokinetics Services Market Revenue (US$ Million), 2021-2031
  • Figure 5. Asia Pacific Pharmacokinetics Services Market Share (%) - by Drug Type (2023 and 2031)
  • Figure 6. Small Molecule: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 7. Large Molecule: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 8. Vaccines: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 9. Asia Pacific Pharmacokinetics Services Market Share (%) - by Service Type (2023 and 2031)
  • Figure 10. Pre-Clinical ADME and Human Studies: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 11. PK/PD Analysis and Reporting: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 12. Dosing Simulations: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 13. Risk Analysis: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 14. Others: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 15. Asia Pacific Pharmacokinetics Services Market Share (%) - by Therapeutic Application (2023 and 2031)
  • Figure 16. Oncology: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 17. Infectious Diseases: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 18. Neurological Disorders: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 19. Autoimmune Diseases: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 20. Gynecological Disorders: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 21. Cardiovascular Diseases: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 22. Respiratory Disorders: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 23. Others: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 24. Asia Pacific Pharmacokinetics Services Market Share (%) - by End User (2023 and 2031)
  • Figure 25. Pharmaceutical and Biotechnology Companies: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 26. Contract Research Organization: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 27. Others: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 28. Asia Pacific Pharmacokinetics Services Market - Revenue by Key Countries 2023 (US$ Million)
  • Figure 29. Asia Pacific Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 30. China: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 31. Japan: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 32. India: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 33. Australia: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 34. South Korea: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 35. Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)